ROTUNNO, GIADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.770
EU - Europa 3.390
AS - Asia 2.175
SA - Sud America 306
Continente sconosciuto - Info sul continente non disponibili 142
AF - Africa 55
OC - Oceania 19
Totale 11.857
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.669
RU - Federazione Russa 1.086
IT - Italia 785
SG - Singapore 636
CN - Cina 597
PL - Polonia 480
HK - Hong Kong 303
BR - Brasile 241
IE - Irlanda 219
VN - Vietnam 199
SE - Svezia 184
KR - Corea 168
DE - Germania 128
FR - Francia 115
FI - Finlandia 113
GB - Regno Unito 90
CH - Svizzera 70
CA - Canada 65
IN - India 60
JO - Giordania 40
BD - Bangladesh 38
NL - Olanda 34
ID - Indonesia 25
AR - Argentina 24
ES - Italia 23
AU - Australia 19
IQ - Iraq 17
JP - Giappone 15
PK - Pakistan 13
CI - Costa d'Avorio 12
MX - Messico 11
EC - Ecuador 10
UZ - Uzbekistan 10
UA - Ucraina 9
ZA - Sudafrica 9
AT - Austria 8
BE - Belgio 8
NG - Nigeria 8
VE - Venezuela 8
BG - Bulgaria 7
CO - Colombia 7
KE - Kenya 7
PH - Filippine 7
TR - Turchia 7
TW - Taiwan 7
CR - Costa Rica 6
MY - Malesia 6
PY - Paraguay 6
SA - Arabia Saudita 6
TN - Tunisia 6
PE - Perù 5
AE - Emirati Arabi Uniti 4
HU - Ungheria 4
AL - Albania 3
CL - Cile 3
EG - Egitto 3
JM - Giamaica 3
LV - Lettonia 3
MA - Marocco 3
PR - Porto Rico 3
RO - Romania 3
TT - Trinidad e Tobago 3
BJ - Benin 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
IL - Israele 2
IM - Isola di Man 2
KZ - Kazakistan 2
MT - Malta 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
BT - Bhutan 1
BY - Bielorussia 1
CG - Congo 1
CU - Cuba 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
IR - Iran 1
KH - Cambogia 1
KW - Kuwait 1
LT - Lituania 1
NI - Nicaragua 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 11.714
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.096
Ashburn 678
Warsaw 473
Singapore 432
Fairfield 414
Hong Kong 259
Woodbridge 228
Chandler 222
San Jose 222
Dublin 219
Seattle 204
Seoul 168
Houston 159
Cambridge 158
Wilmington 147
Beijing 145
Florence 116
Ann Arbor 112
Hefei 105
Milan 99
Altamura 82
Lawrence 80
Los Angeles 77
Buffalo 75
Bern 70
Ho Chi Minh City 62
The Dalles 61
Council Bluffs 60
Princeton 60
Dallas 58
Munich 52
Lauterbourg 51
New York 51
Chicago 50
Helsinki 48
Hanoi 42
Boston 41
Rome 40
Moscow 34
Turku 34
Shanghai 32
San Diego 31
Bremen 30
London 29
Mumbai 27
Clifton 26
Paris 26
São Paulo 26
Kent 24
Medford 21
Atlanta 20
Phoenix 20
Melbourne 18
Boardman 17
Naples 17
Orem 17
Redondo Beach 17
Montreal 16
Barcelona 15
Jakarta 15
Brooklyn 14
Abidjan 12
Amsterdam 12
Dearborn 12
Dong Ket 12
Tokyo 12
Hillsboro 11
Frankfurt am Main 10
Palermo 10
Tashkent 10
Turin 10
Brescia 9
Denver 9
Norwalk 9
Abuja 8
Brussels 8
Chennai 8
Claymont 8
Da Nang 8
Figino 8
Fuzhou 8
Guangzhou 8
Hangzhou 8
Johannesburg 8
Toronto 8
Baghdad 7
Cagliari 7
Dhaka 7
Nairobi 7
Pune 7
San Francisco 7
Biên Hòa 6
Fiesole 6
Haiphong 6
Manchester 6
Pian di Scò 6
San José 6
Tianjin 6
Venice 6
Vienna 6
Totale 7.564
Salva come PNG Salva come JPEG
Nome #
Study of mutation complexity in Chronic Myeloproliferative Neoplasms: pathogenetic insights and translational relevance 410
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 404
Validation of the Mayo alliance prognostic system for mastocytosis 347
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 338
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 311
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing 295
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 259
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 257
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 254
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 238
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 235
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 235
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 226
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 226
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 214
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 214
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 213
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 206
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 205
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 205
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 202
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 201
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 201
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 200
Mutations and prognosis in primary myelofibrosis. 200
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 199
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 196
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 194
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 191
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 190
CALR mutation burden in essential thrombocythemia and disease outcome 188
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. 188
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 183
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 182
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 180
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 179
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 174
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 172
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 172
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 165
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 165
Prognotic Impact of Mutations in Systemic Mastocytosis 161
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. 160
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 158
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 158
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 157
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice? 157
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 157
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML 155
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 153
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 146
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 143
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 143
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 143
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients 140
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 134
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting 125
Prognostic relevance of mutations in myelofi-brosis 120
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia. 56
null 47
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis 30
Totale 11.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.584
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.584
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022314 0 0 0 17 20 21 13 40 20 14 74 95
2022/20231.160 87 228 72 79 71 173 140 89 103 13 26 79
2023/2024481 25 40 64 18 51 60 12 102 11 32 34 32
2024/20253.139 84 283 196 502 845 494 72 144 130 101 141 147
2025/20263.369 423 408 302 322 384 122 377 119 207 226 127 352
2026/2027868 163 392 271 42 0 0 0 0 0 0 0 0
Totale 11.857